Colon‐targeted complement C5a 1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70056 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Cedric S Cui and 11 co-authors. Institution: School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Major MEDLINE topics: Nanoparticles, Receptor, Anaphylatoxin C5a, Colon, Colitis. Cited 9 times so far (Crossref); 68 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council.
Abstract (original language)
Background and Purpose The complement system is associated with inflammatory bowel disease (IBD) pathology. Complement activation induces C5a production, which signals through the C5a 1 receptor (C5aR1) to drive inflammatory responses that may underlie IBD. Experimental Approach We examined mucosal biopsies from ulcerative colitis patients and identified C5a 1 receptor up‐regulated in active lesions, supporting the C5a 1 receptor as a target for therapeutic intervention. Cyclic peptide C5a 1 receptor antagonists such as PMX205 are orally efficacious in preclinical colitis models; however, their clinical application may be limited by rapid metabolism. We therefore encapsulated PMX205 within pH‐sensitive polymers to target drug for colon delivery following oral administration. Key Results PMX205 nanoparticles were non‐toxic and released bioactive PMX205 in simulated colon fluid. In vivo imaging of Cy5‐labelled nanoparticles demonstrated rapid entry and persistence in the mouse colon for up to 48 h. Next, we utilised the dextran sodium sulphate‐induced colitis model to examine efficacy of the C5a 1 receptor‐antagonist formulation. We show that oral administration of PMX205 nanoparticles every 2 days from symptom onset significantly mitigated weight loss, clinical illness, colon length reduction and epithelial damage to a similar degree as C5a 1 receptor −/− mice. Notably, unformulated PMX205 was markedly less effective in this dosing regimen. Conclusion and Implications This novel colon‐targeted formulation therefore offers a potent therapeutic strategy for translating C5a 1 receptor antagonists for IBD conditions such as ulcerative colitis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
- Mater Research Institute, Translational Research Institute, Brisbane, Queensland, Australia.
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland, Australia.
ORCID profiles: Cedric S Cui, Vinod Kumar, John D Lee, Trent M Woodruff
Funding
- National Health and Medical Research Council
Cite
APA
Cui, C. S., Lerskiatiphanich, T., Li, X. X., Giri, R., Liu, N., Kumar, V., Whittaker, A. K., Han, F. Y., Clark, R. J., Begun, J., Lee, J. D., & Woodruff, T. M. (2025). Colon‐targeted complement C5a 1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology. https://doi.org/10.1111/bph.70056
Vancouver
Cui CS, Lerskiatiphanich T, Li XX, Giri R, Liu N, Kumar V, et al. Colon‐targeted complement C5a 1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology. 2025. doi:10.1111/bph.70056
BibTeX
@article{Cui2025,
author = {Cui, Cedric S and Lerskiatiphanich, Titaya and Li, Xaria X and Giri, Rabina and Liu, Ning and Kumar, Vinod and Whittaker, Andrew K and Han, Felicity Y and Clark, Richard J and Begun, Jakob and Lee, John D and Woodruff, Trent M},
title = {Colon‐targeted complement C5a 1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70056}
}
EUVIMED